Clinical trials of NK cells for cancer

Natural Killer Cells

Volumn , Issue , 2010, Pages 555-570

  Cooley, Sarah ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859118991     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-370454-2.00043-0     Document Type: Chapter

References (132)

1. Ames E., Hallett W.H., Murphy W.J. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 2009, 155(3):504-513.
2. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., Breso V., Frassati C., Reviron D., Middleton D., Romagne F., Ugolini S., Vivier E. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25(2):331-342.
3. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10(6):625-632.
4. Armeanu S., Bitzer M., Lauer U.M., Venturelli S., Pathil A., Krusch M., Kaiser S., Jobst J., Smirnow I., Wagner A., Steinle A., Salih H.R. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65(14):6321-6329.
5. Barao I., Hanash A.M., Hallett W., Welniak L.A., Sun K., Redelman D., Blazar B.R., Levy R.B., Murphy W.J. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006, 103(14):5460-5465.
6. Becknell B., Caligiuri M.A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005, 86:209-239.
7. Beelen D.W., Ottinger H.D., Ferencik S., Elmaagacli A.H., Peceny R., Trenschel R., Grosse-Wilde H. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005, 105(6):2594-2600.
8. Berg, M., A. Lundqvist, P. mcCoy, L. Samsel, Y. Fan, A. Tawab, R. Childs (2009), "Clinical Grade Ex Vivo-Expanded Human Natural Killer Cells Upregulate Activating Receptors and Death Receptor Ligands and Have Enhanced Cytolytic Activity against Tumor Cells." Cytotherapy, in press.
9. Berger M., Ablasser A., Kim S., Bekeredjian-Ding I., Giese T., Endres S., Hornung V., Hartmann G. TLR8-driven IL-12-dependent Reciprocal and Synergistic Activation of NK Cells and Monocytes by Immunostimulatory RNA. J Immunother 2009, 32(3):262-272.
10. Bishara A., De Santis D., Witt C.C., Brautbar C., Christiansen F.T., Or R., Nagler A., Slavin S. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004, 63(3):204-211.
11. Bottino C., Castriconi R., Moretta L., Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005, 26(4):221-226.
12. Brunstein, C., J. E. Wagner, D. J. Weisdorf, S. Cooley, H. Noreen, J. N. Barker, T. Defor, M. R. Verneris, B. R. Blazar and J. S. Miller (2009). "Negative Effect of KIR Alloreactivity in Recipients of Umbilical Cord Blood Transplantation Depends on Transplantation Conditioning Intensity." Blood, In Press.
13. Burns L.J., Weisdorf D.J., DeFor T.E., Vesole D.H., Repka T.L., Blazar B.R., Burger S.R., Panoskaltsis-Mortari A., Keever-Taylor C.A., Zhang M.J., Miller J.S. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32(2):177-186.
14. Cao W., Xi X., Hao Z., Li W., Kong Y., Cui L., Ma C., Ba D., He W. RAET1E2, a soluble isoform of the UL16 binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem 2007, 282(26):18922-18928.
15. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., Anderson D., Eisenmann J., Grabstein K., Caligiuri M.A. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994, 180(4):1395-1403.
16. Chan H.W., Miller J.S., Moore M.B., Lutz C.T. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol 2005, 175(9):5966-5974.
17. Chen C., Busson M., Rocha V., Appert M.L., Lepage V., Dulphy N., Haas P., Socie G., Toubert A., Charron D., Loiseau P. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006, 38(6):437-444.
18. Chrysler G., McKenna D.H., Schierman T., et al. Umbilical cord blood banking 2004, AABB Press, Bethsesda, MD.
19. Cook M., Briggs D., Craddock C., Mahendra P., Milligan D., Fegan C., Darbyshire P., Lawson S., Boxall E., Moss P. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006, 107(3):1230-1232.
20. Cook M.A., Milligan D.W., Fegan C.D., Darbyshire P.J., Mahendra P., Craddock C.F., Moss P.A., Briggs D.C. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004, 103(4):1521-1526.
21. Cooley S., Burns L.J., Repka T., Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999, 27(10):1533-1541.
22. Cooley, S., Gada, P., McKenna, D., McCullar, V., Fautsch, S., Verneris, M.R., Blazar, B., Burns, L.J., McGlave, P., Weisdorf, D. and Miller, J. (2008). Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells: Abstract #8517. Blood 112.
23. Cooley S., McCullar V., Wangen R., Bergemann T.L., Spellman S., Weisdorf D.J., Miller J.S. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106(13):4370-4376.
24. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., Marsh S.G., Guethlein L.A., Parham P., Miller J.S., Weisdorf D.J. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113(3):726-732.
25. Cooley S., Xiao F., Pitt M., Gleason M., McCullar V., Bergemann T.L., McQueen K.L., Guethlein L.A., Parham P., Miller J.S. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007, 110(2):578-586.
26. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22(11):633-640.
27. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med 1971, 134(1):83-102.
28. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971, 134(6):1513-1528.
29. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64(13):4664-4669.
30. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594):850-854.
31. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26(32):5233-5239.
32. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., Theofilopoulos A.N. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002, 110(2):185-192.
33. Farrell H.E., Vally H., Lynch D.M., Fleming P., Shellam G.R., Scalzo A.A., Davis-Poynter N.J. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997, 386(6624):510-514.
34. Fauriat C., Andersson S., Bjorklund A.T., Carlsten M., Schaffer M., Bjorkstrom N.K., Baumann B.C., Michaelsson J., Ljunggren H.G., Malmberg K.J. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 2008, 181(9):6010-6019.
35. Fehniger T.A., Suzuki K., Ponnappan A., VanDeusen J.B., Cooper M.A., Florea S.M., Freud A.G., Robinson M.L., Durbin J., Caligiuri M.A. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001, 193(2):219-231.
36. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105(11):4416-4423.
37. Foley B.A., De Santis D., Van Beelen E., Lathbury L.J., Christiansen F.T., Witt C.S. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008, 112(2):435-443.
38. Freud A.G., Yokohama A., Becknell B., Lee M.T., Mao H.C., Ferketich A.K., Caligiuri M.A. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203(4):1033-1043.
39. Gasser S., Raulet D.H. Activation and self-tolerance of natural killer cells. Immunol Rev 2006, 214:130-142.
40. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., Maccario R., Bonetti F., Wojnar J., Martinetti M., Frassoni F., Giorgiani G., Bacigalupo A., Holowiecki J. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102(3):814-819.
41. Godal, R., M. Gleason, V. McCullar, S. Cooley, V. Bachanova, M. Verneris, P. McGlave, J. S. Miller (2008). "Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade ASH Abstract #2906 Sunday, December 7, 2008, 6:00 PM-8:00 PM.".
42. Hallett W.H.D., Ames E., Motarjemi M., Barao I., Shanker A., Tamang D.L., Sayers T.J., Hudig D., Murphy W.J. Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition. J Immunol 2008, 180(1):163-170.
43. Herberman R.B., Ortaldo J.R. Natural killer cells: their roles in defenses against disease. Science 1981, 214(4516):24-30.
44. Houchins J.P., Yabe T., McSherry C., Bach F.H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991, 173(4):1017-1020.
45. Hsu K.C., Gooley T., Malkki M., Pinto-Agnello C., Dupont B., Bignon J.D., Bornhauser M., Christiansen F., Gratwohl A., Morishima Y., Oudshoorn M., Ringden O., van Rood J.J., Petersdorf E. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12(8):828-836.
46. Hsu K.C., Keever-Taylor C.A., Wilton A., Pinto C., Heller G., Arkun K., O'Reilly R.J., Horowitz M.M., Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105(12):4878-4884.
47. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., CorcuffE., Mortier E., Jacques Y., Spits H., Di Santo J.P. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009, 206(1):25-34.
48. Igarashi T., Wynberg J., Srinivasan R., Becknell B., McCoy J.P., Takahashi Y., Suffredini D.A., Linehan W.M., Caligiuri M.A., Childs R.W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004, 104(1):170-177.
49. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106(1):376-383.
50. Kiessling R., Petranyi G., Klein G., Wigzel H. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer 1975, 15(6):933-940.
51. Kikuchi-Maki A., Yusa S., Catina T.L., Campbell K.S. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol 2003, 171(7):3415-3425.
52. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., French A.R., Sunwoo J.B., Lemieux S., Hansen T.H., Yokoyama W.M. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436(7051):709-713.
53. Koehl U., Esser R., Zimmermann S., Tonn T., Kotchetkov R., Bartling T., Sorensen J., Gruttner H.P., Bader P., Seifried E., Martin H., Lang P., Passweg J.R., Klingebiel T., Schwabe D. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 2005, 217(6):345-350.
54. Koh C.Y., Blazar B.R., George T., Welniak L.A., Capitini C.M., Raziuddin A., Murphy W.J., Bennett M. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001, 97(10):3132-3137.
55. Kroger N., Binder T., Zabelina T., Wolschke C., Schieder H., Renges H., Ayuk F., Dahlke J., Eiermann T., Zander A. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82(8):1024-1030.
56. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
57. Lanier L.L., Ruitenberg J.J., Phillips J.H. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988, 141(10):3478-3485.
58. Leung W., Iyengar R., Triplett B., Turner V., Behm F.G., Holladay M.S., Houston J., Handgretinger R. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174(10):6540-6545.
59. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11(7):237-244.
60. Lopez-Botet M., Angulo A., Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 2004, 63(3):195-203.
61. Lopez-Vazquez A., Rodrigo L., Martinez-Borra J., Perez R., Rodriguez M., Fdez-Morera J.L., Fuentes D., Rodriguez-Rodero S., Gonzaez S., Lopez-Larrea C. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2005, 192(1):162-165.
62. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., Woodard P., Leung W. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123(2):323-326.
63. Lundqvist A., Abrams S.I., Schrump D.S., Alvarez G., Suffredini D., Berg M., Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66(14):7317-7325.
64. Lundqvist A., Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J Immunother (1997) 2005, 28(4):281-288.
65. Lundqvist A., McCoy J.P., Samsel L., Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007, 109(8):3603-3606.
66. Lundqvist A., Yokoyama H., Smith A., Berg M., Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the anti-tumor effects of adoptively infused NK cells. Blood 2009, 113(24):6042-6043.
67. Malmberg K.J., Bryceson Y.T., Carlsten M., Andersson S., Bjorklund A., Bjorkstrom N.K., Baumann B.C., Fauriat C., Alici E., Dilber M.S., Ljunggren H.G. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 2008, 57(10):1541-1552.
68. Marsh S.G., Parham P., Dupont B., Geraghty D.E., Trowsdale J., Middleton D., Vilches C., Carrington M., Witt C., Guethlein L.A., Shilling H., Garcia C.A., Hsu K.C., Wain H. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens 2003, 62(1):79-86.
69. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., Colombo S., Brown E.E., Shupert W.L., Phair J., Goedert J.J., Buchbinder S., Kirk G.D., Telenti A., Connors M., O'Brien S.J., Walker B.D., Parham P., Deeks S.G., McVicar D.W., Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39(6):733-740.
70. Maxwell L.D., Wallace A., Middleton D., Curran M.D. A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey. Tissue Antigens 2002, 60(3):254-258.
71. McKenna D.H., Sumstad D., Bostrom N., Kadidlo D.M., Fautsch S., McNearney S., Dewaard R., McGlave P.B., Weisdorf D.J., Wagner J.E., McCullough J., Miller J.S. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007, 47(3):520-528.
72. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007, 68(5):309-323.
73. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008, 83(4):799-803.
74. Miller J.S., Cooley S., Parham P., Farag S.S., Verneris M.R., McQueen K.L., Guethlein L.A., Trachtenberg E.A., Haagenson M., Horowitz M.M., Klein J.P., Weisdorf D.J. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109(11):5058-5061.
75. Miller J.S., McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 2001, 98(3):705-713.
76. Miller J.S., Oelkers S., Verfaillie C., McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992, 80(9):2221-2229.
77. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., Orchard P.J., Blazar B.R., Wagner J.E., Slungaard A., Weisdorf D.J., Okazaki I.J., McGlave P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105(8):3051-3057.
78. Moesta A.K., Norman P.J., Yawata M., Yawata N., Gleimer M., Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008, 180(6):3969-3979.
79. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M.C., Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006, 18(3):151-158.
80. Moretta L., Ferlazzo G., Bottino C., Vitale M., Pende D., Mingari M.C., Moretta A. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006, 214:219-228.
81. Muench M.O., Humeau L., Paek B., Ohkubo T., Lanier L.L., Albanese C.T., Barcena A. Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors. Exp Hematol 2000, 28(8):961-973.
82. Muranski P., Boni A., Wrzesinski C., Citrin D.E., Rosenberg S.A., Childs R., Restifo N.P. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat Clin Pract Oncol 2006, 3(12):668-681.
83. Murphy W.J., Keller J.R., Harrison C.L., Young H.A., Longo D.L. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1992, 80(3):670-677.
84. Murphy W.J., Kumar V., Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 1987, 166(5):1499-1509.
85. Ohira M., Ohdan H., Mitsuta H., Ishiyama K., Tanaka Y., Igarashi Y., Asahara T. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006, 82(12):1712-1719.
86. Pando M.J., Gardiner C.M., Gleimer M., McQueen K.L., Parham P. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003, 171(12):6640-6649.
87. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006, 214:155-160.
88. Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kuhne T., Favre G., Gratwohl A. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18(11):1835-1838.
89. Pende D., Spaggiari G.M., Marcenaro S., Martini S., Rivera P., Capobianco A., Falco M., Lanino E., Pierri I., Zambello R., Bacigalupo A., Mingari M.C., Moretta A., Moretta L. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105(5):2066-2073.
90. Pessino A., Sivori S., Bottino C., Malaspina A., Morelli L., Moretta L., Biassoni R., Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998, 188(5):953-960.
91. Prlic M., Blazar B.R., Farrar M.A., Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003, 197(8):967-976.
92. Raulet D.H. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 2006, 18(3):145-150.
93. Raulet D.H., Vance R.E., McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
94. Rayner A.A., Grimm E.A., Lotze M.T., Chu E.W., Rosenberg S.A. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985, 55(6):1327-1333.
95. Re F., Staudacher C., Zamai L., Vecchio V., Bregni M. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 2006, 107(3):640-648.
96. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316(15):889-897.
97. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., Aebersold P., Leitman S., Linehan W.M., Seipp C.A., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85(8):622-632.
98. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097-2100.
99. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., Stern M., Pende D., Perruccio K., Burchielli E., Topini F., Bianchi E., Aversa F., Martelli M.F., Velardi A. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110(1):433-440.
100. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370.
101. Shi J., Tricot G., Szmania S., Rosen N., Garg T.K., Malaviarachchi P.A., Moreno A., Dupont B., Hsu K.C., Baxter-Lowe L.A., Cottler-Fox M., Shaughnessy J.D., Barlogie B., van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143(5):641-653.
102. Shi J., Tricot G.J., Garg T.K., Malaviarachchi P.A., Szmania S.M., Kellum R.E., Storrie B., Mulder A., Shaughnessy J.D., Barlogie B., van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008, 111(3):1309-1317.
103. Shilling H.G., McQueen K.L., Cheng N.W., Shizuru J.A., Negrin R.S., Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003, 101(9):3730-3740.
104. Shlomchik W.D., Couzens M.S., Tang C.B., McNiffJ., Robert M.E., Liu J., Shlomchik M.J., Emerson S.G. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285(5426):412-415.
105. Siefer A.K., Longo D.L., Harrison C.L., Reynolds C.W., Murphy W.J. Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood 1993, 82(8):2577-2584.
106. Singh S.M., Yanagawa H., Hanibuchi M., Miki T., Okamura H., Sone S. Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. Int J Immunopharmacol 2000, 22(1):35-43.
107. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., Cippitelli M., Fionda C., Petrucci M.T., Guarini A., Foa R., Santoni A. ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. Blood 2008, 113(15):3503-3511.
108. Stein M.N., Shin J., Gudzowaty O., Bernstein A.M., Liu J.M. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 2006, 26(3A):1759-1763.
109. Stern M., Elsasser H., Honger G., Steiger J., Schaub S., Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 2008, 8(6):1312-1317.
110. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006, 16(5):412-418.
111. Suck G., Branch D.R., Smyth M.J., Miller R.G., Vergidis J., Fahim S., Keating A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 2005, 33(10):1160-1171.
112. Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., Rowland-Jones S. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007, 178(1):33-37.
113. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2):133-146.
114. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(3):179-190.
115. Trompeter H.I., Gomez-Lozano N., Santourlidis S., Eisermann B., Wernet P., Vilches C., Uhrberg M. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol 2005, 174(7):4135-4143.
116. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H.G., Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100(4):1265-1273.
117. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7(6):753-763.
118. Vales-Gomez M., Reyburn H.T., Mandelboim M., Strominger J.L. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 1998, 9(3):337-344.
119. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., Phillips J.H., Lanier L.L., Parham P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997, 7(6):739-751.
120. Verhoeven D.H., de Hooge A.S., Mooiman E.C., Santos S.J., ten Dam M.M., Gelderblom H., Melief C.J., Hogendoorn P.C., Egeler R.M., van Tol M.J., Schilham M.W., Lankester A.C. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008, 45(15):3917-3925.
121. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., Augugliaro R., Moretta L., Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187(12):2065-2072.
122. Vitale M., Castriconi R., Parolini S., Pende D., Hsu M.L., Moretta L., Cosman D., Moretta A. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol 1999, 11(1):29-35.
123. Voigt V., Forbes C.A., Tonkin J.N., Degli-Esposti M.A., Smith H.R., Yokoyama W.M., Scalzo A.A. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci U S A 2003, 100(23):13483-13488.
124. Walzer T., Dalod M., Robbins S.H., Zitvogel L., Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force. Blood 2005, 106(7):2252-2258.
125. Wang X., Rickert M., Garcia K.C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005, 310(5751):1159-1163.
126. Willemze R., Rodrigues C.A., Labopin M., Sanz G., Michel G., Socie G., Rio B., Sirvent A., Renaud M., Madero L., Mohty M., Ferra C., Garnier F., Loiseau P., Garcia J., Lecchi L., Kogler G., Beguin Y., Navarrete C., Devos T., Ionescu I., Boudjedir K., Herr A.L., Gluckman E., Rocha V. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23(3):492-500.
127. Woll P.S., Martin C.H., Miller J.S., Kaufman D.S. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 2005, 175(8):5095-5103.
128. Yawata M., Yawata N., Abi-Rached L., Parham P. Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol 2002, 22(5-6):463-482.
129. Yokoyama W.M., Daniels B.F., Seaman W.E., Hunziker R., Margulies D.H., Smith H.R. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995, 7(2):89-101.
130. Yokoyama W.M., Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006, 214:143-154.
131. Young H.A., Ortaldo J. Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res 2006, 16(1):20-24.
132. Yu H., Fehniger T.A., Fuchshuber P., Thiel K.S., Vivier E., Carson W.E., Caligiuri M.A. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998, 92(10):3647-3657.